Carruthers Wendy, EVP of Human Resources at Boston Scientific (BSX), has demonstrated a clear selling bias in her recent insider transactions, with no open-market purchases recorded in the past year. Since February 2024, she has executed five sales of BSX stock totaling over $2.98 million, including a $526,029 transaction on June 3 and a $499,075 sale on May 1. These disposals follow a pattern of monthly sales beginning February 23, when she sold $467,093 worth of shares. The transactions appear systematic, with each sale accompanied by smaller "M"-coded transactions likely representing tax withholdings or other mandatory dispositions.
Prior to these sales, Carruthers acquired BSX shares through equity awards in February 2024, including four "F"-coded acquisitions totaling $241,615 at prices ranging from $59,896 to $65,688. However, her overall activity skews heavily toward divestment, with total sales outpacing buys by a 7:1 ratio ($2.99 million sold versus $411,528 bought). The consistency of her selling—occurring monthly from February through June—suggests a structured liquidation plan rather than discretionary market timing. All transactions relate exclusively to BSX, indicating concentrated exposure to her employer's stock prior to these reductions.
AI-assisted summary